AVLN insider transaction filings
Avalyn Pharma Inc. — 14 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-05. Screen AVLN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-05 | 4 | FMR LLC — 10% owner | Conversion (C): 727,585 · Conversion (C): 80,291 · Conversion (C): 872,868 · Conversion (C): 225,843 · Conversion (C): 377,948 · Conversion (C): 727,585 (derivative) · +4 more | EDGAR |
| 2026-05-05 | 4 | Novo Holdings A/S — 10% owner | Conversion (C): 3,327,734 · Purchase (P): 555,555 @ $18 · Conversion (C): 18,000,000 (derivative) @ $0 · Conversion (C): 1,986,369 (derivative) @ $0 · Conversion (C): 25,899,284 (derivative) @ $0 · Conversion (C): 5,587,603 (derivative) @ $0 · +1 more | EDGAR |
| 2026-05-04 | 4 | Golden Adam H. — General Counsel | Grant/award (A): 254,891 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Carroll Jill — Director | Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 27,309,719 (derivative) · Conversion (C): 9,418,561 (derivative) | EDGAR |
| 2026-05-01 | 4 | SR ONE CAPITAL MANAGEMENT, LLC — 10% owner George Simeon — 10% owner | Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 354,824 · Conversion (C): 489,486 · Purchase (P): 277,777 @ $18 · +4 more | EDGAR |
| 2026-05-01 | 4 | Congleton Jon — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Rhodes Melissa — Chief Operating Officer | Grant/award (A): 211,975 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Carlson Douglas R — Chief Financial Officer | Grant/award (A): 211,975 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Haviland Kate — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. — 10% owner | Conversion (C): 1,275,486 · Conversion (C): 20,482,289 (derivative) @ $0 · Conversion (C): 4,060,259 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Lazarus Howard — Chief Medical Officer | Grant/award (A): 211,975 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Lavelle Erin — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Baranowski Lyn — Chief Executive Officer, Director | Grant/award (A): 501,033 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Turner Heather D — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
Recent 8-K events — Avalyn Pharma Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-06-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AVLN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →